Karim Fizazi
MD, PhD
Professor of Medicine, Department of Cancer Medicine
👥Biography 个人简介
Karim Fizazi led the LATITUDE trial establishing abiraterone acetate plus prednisone with ADT as a standard of care for high-risk metastatic hormone-sensitive prostate cancer, demonstrating substantial overall survival benefit. His research has shaped the backbone of mHSPC treatment across multiple combination strategies. He has been a key investigator in trials examining abiraterone, darolutamide, and novel AR-targeted agents in hormone-sensitive disease. Fizazi's contributions to understanding prostate cancer biology and treatment sequencing are globally recognized.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Karim Fizazi 的研究动态
Follow Karim Fizazi's research updates
留下邮箱，当我们发布与 Karim Fizazi（Institut Gustave Roussy）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment